CytoMed Therapeutics shares surge 16.11% premarket after securing $500,000 non-dilutive investment from ICH Capital for LongevityBank subsidiary.

CytoMed Therapeutics surged 16.11% in premarket trading following the announcement of a $500,000 non-dilutive investment from ICH Capital for a 10% stake in its subsidiary LongevityBank, which focuses on autologous cell therapies. The funding reinforces CytoMed’s strategy to diversify into personalized cellular banking services while advancing its allogeneic gamma delta T cell platform, currently in Phase I trials in Singapore and Phase II trials in India. Additionally, regulatory developments in China—specifically State Council Decree No. 818—establish a streamlined pathway for cell therapies as biotechnological medical procedures, enabling faster clinical application and potential market access. The company also highlighted patents for its proprietary technologies in China and ongoing partnerships to commercialize low-cost manufacturing methods. These developments collectively signaled progress in product development, regulatory clarity, and capital access, driving the sharp premarket rally.